GleamWall
中文EN

NAGE Niagen Bioscience, Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1386570 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.9%
TTM net income YoY-49.9%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR13.6%
Net income 3-yr CAGR—

Margins

Gross margin63.9%
Operating margin3.9%
Net margin8.4%
FCF margin—
EBITDA margin4.3%

Returns

ROE13.3%
ROA9.9%
ROIC (approx.)44.3%
Asset turnover1.18x

Leverage & solvency

Liabilities / assets23.6%
Debt / equity0.00x
Current ratio5.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$129.42M$99.60M
Cost of revenue$46.23M$38.01M
Gross profit$83.19M$61.59M
R&D expense$6.33M$6.02M
SG&A expense$27.06M$18.38M
Operating income$16.28M$7.73M
Pretax income$18.19M$8.86M
Income tax$810,000$305,000
Net income$17.38M$8.55M
EBITDA$16.89M$8.39M
EPS (basic)0.220.11
EPS (diluted)0.200.11
Weighted avg. shares (diluted)85.44M78.12M
Balance sheet
Cash & equivalents$64.79M$44.66M
Receivables$9.74M$7.77M
Inventory$20.42M$9.19M
Current assets$96.81M$64.10M
PP&E, net$1.32M$1.72M
Intangibles$5.66M$359,000
Total assets$106.41M$68.28M
Current liabilities$19.92M$17.95M
Total liabilities$29.87M$22.18M
Shareholders' equity$76.53M$46.09M
Shares outstanding79.71M77.33M
Cash flow statement
Operating cash flow$13.50M$12.11M
Investing cash flow-$292,000-$143,000
Financing cash flow$6.92M$5.37M
Depreciation & amortization$612,000$663,000
Stock-based compensation$6.07M$3.66M
Share buybacks$251,000$0

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.